YOUR SEARCH FOR Text 22 RESULTS
11 of Total
Incyte Reports 2022 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… neoplasms (MLN): Phase 2 (FIGHT‑203) Glioblastoma: Phase 2 (FIGHT-209) Non-small …
12 of Total
Incyte Reports 2023 Fourth Quarter and Year-End Financial Results, Provides 2024 Financial Guidance
… opportunity for over 10 new launches by 2030 Incyte to host an in-person and webcast … deliver more than ten high impact launches by 2030." Key Product Sales Performance Jakafi: Net …
13 of Total
Incyte Reports 2021 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… Phase 3 (FIGHT-302) 8p11 MPN: Phase 2 (FIGHT-203) Tumor agnostic: Phase 2 (FIGHT-207) … parsaclisib (PI3Kδ) r/r FL: Phase 2 (CITADEL-203) r/r MZL: Phase 2 (CITADEL-204) r/r MCL: …
14 of Total
Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance
… more than 10 impactful product launches by 2030. In 2025, a number of key catalysts across … to have more than 10 high impact launches by 2030; the potential and progress of programs in …
15 of Total
Incyte Reports 2021 Fourth Quarter and Year-End Financial Results, and Provides 2022 Financial Guida
… neoplasms (MLN): Phase 2 (FIGHT‑203) Glioblastoma: Phase 2 in preparation NSCLC: …
16 of Total
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
… track to achieve over ten impactful launches by 2030.” Key Recent Company Updates In October, …
17 of Total
Incyte Reports 2022 First Quarter Financial Results and Provides Updates on Key Clinical Programs |
… neoplasms (MLN): Phase 2 (FIGHT‑203) Glioblastoma: Phase 2 (FIGHT-209) being …
18 of Total
Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs |
View all news Incyte Reports 2023 Third Quarter Financial Results and Provides Updates on Key Clinical Programs October 31, 2023 at 7:00 AM EDT PDF
19 of Total
Incyte Reports 2025 Second Quarter Financial Results and Provides Updates on Key Clinical Programs |
… to have more than 10 high impact launches by 2030; the disease modifying/curative potential …
20 of Total
Medical Information Contact Info US & European Locations | Incyte.com
… 01 70 76 06 36* Germany 08001009633 089 20301 0899* Ireland 1800456748 Italy …